How the MHRA makes decisions on what is a medicinal product (borderline products).
Similar Posts
Field Safety Notices: 23 to 27 June 2025
List of Field Safety Notices from 23 to 27 June 2025.
Supplying authorised medicines to Northern Ireland
What you need to do to supply authorised medicines from Great Britain to Northern Ireland.
Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.Dr Alison Cave: Pharmacists are on the frontline of medicines safety – and your reports make all the difference
As part of #MedSafetyWeek, the MHRA’s Chief Safety Officer reflects in The Pharmacist on the vital role pharmacists play in keeping medicines and medical devices safe.
Corporate report: Human Medicines Regulations 2012 Advisory Bodies Annual Report 2024
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies – the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
Form: Decentralised Manufacture: The designation step application form
Application Form to be completed by an Applicant and sent to the MHRA requesting consideration of an award of a Decentralised Manufacture (DM) Designation.